

Reference:	FOI.8887.22
Subject:	Biologic medicines
Date of Request:	11 May 2022

Requested:

1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of medications dispensed for prescriptions, issued by the Dermatology Department, for any condition, during the period 1 February to 30 April 2022.

Medication	Number dispensed
Adalimumab – Humira	*
Adalimumab Biosimilar	63
Apremilast	13
Bimekizumab	0
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	*
Etanercept – Enbrel	0
Etanercept Biosimilar	*
Guselkumab	*
Infliximab – Remicade	0
Infliximab Biosimilar	0
Ixekizumab	*
Risankizumab	*
Secukinumab	19
Tildrakizumab	0
Ustekinumab	27

2. The UHB provides, within the table below, the number of medications dispensed for prescriptions issued by the Gastroenterology Department, for any condition, during the period 1 February to 30 April 2022.

Medication	Number dispensed
Adalimumab – Humira	37
Adalimumab Biosimilar	83
Filgotinib	0
Golimumab	*
Infliximab – Remicade	*
Infliximab Biosimilar	54
Ozanimod	0
Tofacitinib	*
Ustekinumab	77
Vedolizumab	86

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of medications dispensed, due to the low number of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 and the UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/UK GDPR define personal data as data which relates to a living individual who can be identified solely from that data, or from that data and other information, which is in the possession of the data controller.